|
|
Article: Plexxikon Gets $15M Investment For Diabetes Drug Development.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Senior Staff Writer
Plexxikon Inc. raised $15 million in venture financing to complete a Series B extension round.
The Berkeley, Calif.-based company said the funding would accelerate clinical development plans for its lead product, PLX204. Still in toxicology studies designed to support an investigational new drug application in the fourth quarter, the peroxisome proliferation-activated receptor (PPAR) pan-agonist compound is being developed for diabetes and related cardiovascular complications.
"Our investors have been tracking the company for some time and have seen us establish the platform from the get-go, not only with our internal ...
Related newspaper, magazine, and journal articles:
|
|
Article: PLEXXIKON RAISES $27M PRIVATELY FOR SCAFFOLD DISCOVERY ...
BIOWORLD Today;
April 17, 2002 ;
700+ words
... ... drug leads. Privately held Plexxikon, of Berkeley, Calif ... The funds also will allow Plexxikon to expand space by 10,000 ... Walden International, of San Francisco. New investors included GIMV ... worldwide presence provides Plexxikon with international reach and ...
|
|